Targeting Liver Tumors: Ascelia CEO Expects 2022 Mangoral Launch
Imaging Agent Mangoral Seen Benefiting From Orphan Drug Status
The CEO of Ascelia Pharma is confident of a successful pivotal trial for its non-gadolinium imaging agent for the detection of liver tumors that could benefit kidney disease patients.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.